HIV clinic‐based extended‐release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non‐blinded, randomized non‐inferiority trial.

MLA

Korthuis, P.Todd, et al. “HIV Clinic‐based Extended‐release Naltrexone versus Treatment as Usual for People with HIV and Opioid Use Disorder: A Non‐blinded, Randomized Non‐inferiority Trial.” Addiction, vol. 117, no. 7, July 2022, pp. 1961–71. EBSCOhost, https://doi.org/10.1111/add.15836.

APA

Korthuis, P. T., Cook, R. R., Lum, P. J., Waddell, E. N., Tookes, H., Vergara, R. P., Kunkel, L. E., Lucas, G. M., Rodriguez, A. E., Bielavitz, S., Fanucchi, L. C., Hoffman, K. A., Bachrach, K., Payne, E. H., Collins, J. A., Matthews, A., Oden, N., Jacobs, P., Jelstrom, E., & Sorensen, J. L. (2022). HIV clinic‐based extended‐release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non‐blinded, randomized non‐inferiority trial. Addiction, 117(7), 1961–1971. https://doi.org/10.1111/add.15836

Chicago

Korthuis, P. Todd, Ryan R. Cook, Paula J. Lum, Elizabeth Needham Waddell, Hansel Tookes, Rodriguez, Pamela Vergara, Lynn E. Kunkel, et al. 2022. “HIV Clinic‐based Extended‐release Naltrexone versus Treatment as Usual for People with HIV and Opioid Use Disorder: A Non‐blinded, Randomized Non‐inferiority Trial.” Addiction 117 (7): 1961–71. doi:10.1111/add.15836.